XH001 plus immunotherapy and chemotherapy after pancreatic cancer surgery
Treatments studied
Part of Cancer, Digestive system, Hormones & metabolism clinical trials.
This trial studies a new treatment called XH001 combined with standard immunotherapy and chemotherapy for people whose pancreatic cancer has been surgically removed. The goal is to see if this combination helps prevent the cancer from coming back.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have been diagnosed with pancreatic adenocarcinoma (a type of pancreatic cancer).
- You have had surgery to remove the cancer, and the surgeon was able to take out all or most of it (R0 or R1 resection).
- You did not receive any chemotherapy or radiation before your surgery.
- You are in good physical condition (able to take care of yourself and do light activities).
- Your CA19-9 level (a tumor marker) is less than 100 before starting chemotherapy.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial combines a new vaccine (XH001) with chemotherapy after surgery for pancreatic cancer. The vaccine aims to train your immune system to fight any remaining cancer cells, potentially lowering the chance of the cancer coming back.
This trial tests whether adding the drug ivonescimab to chemotherapy before surgery can help people with borderline resectable pancreatic cancer. The treatment is given for a short time to shrink the tumor and make surgery more likely to succeed.
This trial tests a new kind of immunotherapy for pancreatic cancer that has not been removed by surgery or has spread. It aims to see if the treatment can help shrink or control the cancer, and you may be eligible whether you have had previous chemotherapy or not.
This trial tests a new immunotherapy drug called ivonescimab combined with chemotherapy, with or without another experimental drug (AK117), for people with pancreatic cancer that has spread. The goal is to see if adding these therapies can help shrink tumors or slow the cancer's growth.
This trial tests a new combination of drugs with radiation therapy for people with locally advanced pancreatic cancer that cannot be removed with surgery. The treatment aims to shrink the tumor and improve outcomes.
This trial tests a new combination of drugs (NC410 plus chemotherapy and nivolumab, with or without ipilimumab) for people with metastatic pancreatic cancer who haven't had treatment yet. The goal is to see if adding these immunotherapy agents can help shrink or control the tumor.
Hear when a new Pancreatic cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.